Lisata Therapeutics (LSTA) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	6 Months Ended
	Jun. 30, 2014	Aug. 07, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'NeoStem, Inc.	'
Entity Central Index Key	'0000320017	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	35,252,041

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$32,865,071	$46,133,759
Marketable securities	920,827	0
Accounts receivable, net of allowance for doubtful accounts of $389,809 and $391,829 at June 30, 2014 and December 31, 2013, respectively	2,510,114	1,860,835
Inventory	2,033,011	1,270,223
Prepaid expenses and other current assets	2,525,402	1,561,933
Total current assets	40,854,425	50,826,750
Property, plant and equipment, net	15,639,291	12,844,216
Goodwill	26,079,536	11,117,770
Intangible assets, net	49,363,012	13,875,617
Other assets	1,459,627	1,151,729
Assets, Total	133,395,891	89,816,082
Current Liabilities	'	'
Accounts payable	5,481,229	3,354,908
Accrued liabilities	2,587,328	4,018,026
Notes payable	794,236	381,097
Mortgages payable	218,988	213,112
Derivative liabilities	0	23,175
Unearned revenues	2,830,546	1,816,601
Total current liabilities	11,912,327	9,806,919
Long-term Liabilities	'	'
Deferred income taxes	18,983,288	4,379,226
Notes payable	1,015,681	531,164
Mortgages payable	2,912,282	3,023,609
Acquisition-related contingent consideration	20,640,000	9,450,000
Other long-term liabilities	635,008	598,729
Liabilities	56,098,586	27,789,647
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2014 and December 31, 2013	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 34,939,223 and 27,196,537 shares, at June 30, 2014 and December 31, 2013, respectively	34,939	27,197
Additional paid-in capital	341,369,613	299,594,525
Treasury stock, at cost	-705,742	-705,742
Accumulated deficit	-262,660,679	-236,373,605
Accumulated other comprehensive income	998	0
Total NeoStem, Inc. stockholders' equity	78,039,229	62,542,475
Noncontrolling interests	-741,924	-516,040
Total equity	77,297,305	62,026,435
Liabilities and Equity, Total	$133,395,891	$89,816,082

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$0.00	$0.00
Accounts receivable trade, net of allowance for doubtful accounts	$389,809	$391,829
Preferred Stock, authorized	20,000,000	20,000,000
Common stock, outstanding	34,939,223	27,196,537
Common Stock, authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	34,939,223	27,196,537
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	0.01	0.01
Preferred stock, par value	$0.01	$0.01

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues	$4,488,932	$4,359,406	$8,544,507	$6,883,318
Cost of revenues	3,677,355	4,235,024	7,503,370	6,627,113
Research and development	5,796,022	3,972,127	10,554,535	7,133,453
Selling, general, and administrative	7,446,017	4,322,434	16,416,032	10,124,306
Total operating costs and expenses	16,919,394	12,529,585	34,473,937	23,884,872
Operating loss	-12,430,462	-8,170,179	-25,929,430	-17,001,554
Other income (expense):	'	'	'	'
Other income (expense), net	-185,737	57,950	-375,288	68,556
Interest expense	-105,906	-65,844	-200,062	-109,405
Nonoperating Income (Expense), Total	-291,643	-7,894	-575,350	-40,849
Loss before provision for income taxes and noncontrolling interests	-12,722,105	-8,178,073	-26,504,780	-17,042,403
Provision for income taxes	47,387	447,568	94,796	447,568
Net loss	-12,769,492	-8,625,641	-26,599,576	-17,489,971
Less - loss attributable to noncontrolling interests	-164,474	-50,282	-312,502	-114,036
Net loss attributable to NeoStem, Inc. common stockholders	($12,605,018)	($8,575,359)	($26,287,074)	($17,375,935)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	($0.40)	($0.46)	($0.88)	($0.99)
Weighted average common shares outstanding	31,739,417	18,503,236	29,940,128	17,606,051

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net loss	($12,769,492)	($8,625,641)	($26,599,576)	($17,489,971)
Available for sale securities - net unrealized gain	998	0	998	0
Total other comprehensive income	998	0	998	0
Comprehensive loss	-12,768,494	-8,625,641	-26,598,578	-17,489,971
Comprehensive loss attributable to noncontrolling interests	-164,474	-50,282	-312,502	-114,036
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	($12,604,020)	($8,575,359)	($26,286,076)	($17,375,935)

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
			Series B Preferred Stock [Member]
Beginning Balance at Dec. 31, 2012	$32,820,159	$33,177,129	$100	$16,375	$231,218,615	$0	($197,392,361)	($665,600)	($356,970)
Beginning Balance (shares) at Dec. 31, 2012	'	'	10,000	16,375,365	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-17,489,971	-17,375,935	'	'	'	'	-17,375,935	'	-114,036
Share-based compensation (in shares)	'	'	'	304,402	'	'	'	'	'
Share-based compensation	3,314,197	3,314,197	'	304	3,313,893	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	2,883,847	'	'	'	'	'
Net proceeds from issuance of common stock	14,248,148	14,248,148	'	2,884	14,245,264	'	'	'	'
Proceeds from exercise of options	0	'	'	'	'	'	'	'	'
Proceeds from warrant exercise (in shares)	'	'	'	20,761	'	'	'	'	'
Stock Issued During Period, Value, Warrant Exercises	105,881	105,881	'	21	105,860	'	'	'	'
Warrant Inducements	6,239	6,239	'	'	6,239	'	'	'	'
Ending Balance at Jun. 30, 2013	32,992,175	33,463,181	100	19,584	248,877,393	0	-214,768,296	-665,600	-471,006
Ending Balance (shares) at Jun. 30, 2013	'	'	10,000	19,584,375	'	'	'	'	'
Beginning Balance at Dec. 31, 2013	62,026,435	62,542,475	100	27,197	299,594,525	0	-236,373,605	-705,742	-516,040
Beginning Balance (shares) at Dec. 31, 2013	'	'	10,000	27,196,537	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-26,599,576	-26,287,074	'	'	'	'	-26,287,074	'	-312,502
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	998	998	'	'	'	998	'	'	'
Share-based compensation (in shares)	'	'	'	456,709	'	'	'	'	'
Share-based compensation	5,653,451	5,653,451	'	457	5,652,994	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	1,650,081	'	'	'	'	'
Net proceeds from issuance of common stock	10,149,438	10,149,438	'	1,650	10,147,788	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	'	'	41,136	'	'	'	'	'
Proceeds from exercise of options	230,183	230,183	'	41	230,142	'	'	'	'
Proceeds from warrant exercise (in shares)	'	'	'	265,250	'	'	'	'	'
Stock Issued During Period, Value, Warrant Exercises	1,373,925	1,373,925	'	264	1,373,661	'	'	'	'
Stock Issued During Period, Shares, Acquisitions	'	'	'	5,329,510	'	'	'	'	'
Stock Issued During Period, Value, Acquisitions	24,462,451	24,462,451	'	5,330	24,457,121	'	'	'	'
Change in Ownership in Subsidiary	0	-86,618	'	'	-86,618	'	'	'	86,618
Ending Balance at Jun. 30, 2014	$77,297,305	$78,039,229	$100	$34,939	$341,369,613	$998	($262,660,679)	($705,742)	($741,924)
Ending Balance (shares) at Jun. 30, 2014	'	'	10,000	34,939,223	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($26,599,576)	($17,489,971)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Equity-based compensation expense	5,653,451	3,314,197
Depreciation and amortization	987,698	832,920
Changes in fair value of derivative liability	-23,175	-68,556
Change in acquisition-related contingent consideration	400,000	0
Bad debt recovery	-2,020	-7,178
Deferred income taxes	94,796	447,568
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-944,297	-190,150
Accounts receivable	-602,132	359,163
Inventory	-762,788	1,081,060
Unearned revenues	1,013,946	-1,106,299
Other assets	-106,909	-25,805
Accounts payable, accrued expenses and other liabilities	-1,615,234	-272,718
Net cash used in operating activities	-22,506,240	-13,125,769
Cash flows from investing activities:	'	'
Net cash received in acquisitions	50,894	0
Purchase of marketable securities	-919,829	0
Acquisition of property and equipment	-2,439,266	-268,535
Net cash used in investing activities	-3,308,201	-268,535
Cash flows from financing activities:	'	'
Proceeds from exercise of options	230,183	0
Proceeds from exercise of warrants	1,373,925	105,881
Net proceeds from issuance of common stock	10,149,439	14,248,148
Repayment of mortgage loan	-105,450	-93,070
Proceeds from notes payable	1,340,981	221,218
Repayment of notes payable	-443,325	-96,608
Payment for warrant inducement	0	-6,239
Net cash provided by financing activities	12,545,753	14,379,330
Net (decrease) increase in cash and cash equivalents	-13,268,688	985,026
Cash and cash equivalents at beginning of period	46,133,759	13,737,452
Cash and cash equivalents at beginning of period	32,865,071	14,722,478
Cash paid during the period for:	'	'
Interest	196,200	126,000
Taxes	0	0
Common stock and contingent consideration issued in merger	$35,252,451	$0

The_Business

The Business	6 Months Ended
	Jun. 30, 2014
The Business [Abstract]	'
Nature of Operations [Text Block]	'
	The Business
	Overview
	NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy platforms that work to address the pathology of disease using a person's own cells to amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.
	Our business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that we leverage for the development of our therapeutics while providing service to other companies in the cell therapy industry. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 of California Stem Cell, Inc. ("CSC"), a cell biotechnology corporation that is developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. The lead product candidate in its immunotherapy pipeline is NBS20, also referred to as DC/TC (dendritic cell/tumor cell), and is targeting malignant melanoma initiating cells. This immunotherapy designed to treat Stage IV or recurrent Stage III metastatic melanoma, which has been granted fast track and orphan designation by the Food and Drug Administration ("FDA"), also has a Phase 3 protocol that is the subject of a Special Protocol Assessment ("SPA"). The SPA, indicates that the FDA is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that would serve as the basis for a Biologics License Application ("BLA") that would be filed with the FDA requesting marketing approval of this therapeutic candidate. This protocol calls for enrolling 250 evaluable patients and is expected to be initiated later in 2014. We are evaluating other clinical indications into which we may advance this program, including liver, ovarian and lung cancers.
	We are also currently developing therapies to address ischemia through utilizing CD34 cells. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. NBS10, also referred to as AMR-001, is our most clinically advanced product candidate in our ischemic repair program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing NBS10, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). The last patient in the trial was infused in December 2013 and the last patient six-month follow-up occurred in June 2014. Once the primary end point six-month data is collected, the data set will be locked and analysis will begin.   An abstract for the PreSERVE AMI study has been accepted for presentation at the American Heart Association's Scientific Sessions being held November 15-19, 2014 although we anticipate results of the study will be released earlier. If approved by the FDA and/or other worldwide regulatory agencies following successful completion of further trials, NBS10 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We are evaluating other clinical indications into which we may advance this program, including traumatic brain injury ("TBI"), congestive heart failure ("CHF"), and critical limb ischemia ("CLI").
	Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system.  Collaborating with the University of California, San Francisco, we are utilizing the technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function.  Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, while in allergic diseases, like asthma, it is though that the immune system overreacts to harmless foreign substances. We plan to initiate in 2014, subject to review and approval of the protocols by the appropriate regulatory authorities, a Phase 2 study of NBS03D, a Treg based therapeutic, in the treatment of type 1 diabetes, and a Phase 1 study in Canada of NBS03A, a Treg based therapeutic, in support of our steroid resistant asthma development program.
	Pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall  healthcare costs.  We are working on a Department of Defense funded study of VSELsTM for the treatment of chronic wounds. Other preclinical work with VSELsTM includes exploring macular degeneration as a target indication.
	Progenitor Cell Therapy, LLC ("PCT") is a contract manufacturer in the cellular therapy industry that generates revenue. This wholly owned subsidiary, which we acquired in 2011, is an industry leader in providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce the capital investment required for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally. Additionally, with our acquisition of CSC in Irvine, California, we are now in a position to leverage NeoStem Oncology's expertise in immunotherapy and advance our platform technology, as well as the technologies of PCT's client base.
	Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to provide value to stockholders by taking advantage of the infrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding NBS20, our DC/TC product candidate and a late stage novel proprietary cancer cell therapy into our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our strong manufacturing capability, we believe the stage is set for us to realize meaningful clinical development and manufacturing efficiencies, further positioning NeoStem to lead the cell therapy industry.
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of June 30, 2014 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2013 and 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2013. Operating results for the six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
	Reclassifications
	Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three and six months ended June 30, 2013 to conform to the presentation for the three and six months ended June 30, 2014.
	Principles of Consolidation
	The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	90%	United States of America
	PCT Allendale, LLC	100%	United States of America
	NeoStem Oncology, LLC (2)	100%	United States of America
	(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of June 30, 2014, BD's ownership interest in Athelos was decreased to 10.0%, and our ownership increased to 90.0%. As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.
	(2) On May 8, 2014, NeoStem acquired CSC, now known as NeoStem Oncology, LLC (see Note 3, Acquisition). Accordingly, the operating results of NeoStem Oncology, LLC prior to May 8, 2014 are not included in the Company's consolidated operations and cash flows.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	Summary of Significant Accounting Policies
	In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no changes during the six months ended June 30, 2014.
	Cash and Cash Equivalents
	Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
	Marketable Securities
	The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
	Inventories
	The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory primarily represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.
	Goodwill and Other Intangible Assets
	Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") programs acquired in the Amorcyte and CSC acquisitions, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.
	The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value.
	Amortized intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives.
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.
	Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.
	Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended June 30, 2014 and 2013, clinical services reimbursements were $1.1 million and $0.4 million, respectively. For the six months ended June 30, 2014 and 2013, clinical services reimbursements were $1.8 million and $0.8 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.
	New Accounting Pronouncement
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Acquisition_Notes

Acquisition (Notes)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	'
	Acquisition
	On May 8, 2014 (the “Closing”), NeoStem closed its acquisition of CSC (the “CSC Acquisition”), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem, CSC, NBS Acquisition Sub I, Inc., a Delaware corporation and a wholly-owned subsidiary of NeoStem (“Subco”), NBS Acquisition Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of NeoStem (“Subco II”), and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement.
	Pursuant to the Merger Agreement, on the Closing Date, (1) Subco was merged with and into CSC (the “First Merger”) and (2) CSC was then merged with and into Subco II (the “Second Merger”, and collectively with the First Merger, the “Mergers”), with Subco II surviving the Mergers as a wholly-owned subsidiary of NeoStem. At Closing, Subco II changed its legal name to NeoStem Oncology, LLC.
	CSC is a biopharmaceutical company with deep expertise in stem cell biology that is engaged in the development of therapies using a patient’s own, i.e., autologous, cells. Its development efforts are primarily directed at immunotherapies for cancer. Its most advanced program is an immunotherapy, NBS20, also referred to as DC/TC (dendritic cell/tumor cell), which uses patients’ own tumor cells to maximize the ability of their immune system to identify and eliminate the cancer initiating cells that are capable of reconstituting or developing new tumors (i.e., “cancer stem cells” or “replicating cells”). The current focus of that program is the treatment of metastatic melanoma. As a result of encouraging Phase 2 data, the Company expects to initiate a Phase 3 clinical trial later in 2014, for which it has received Special Protocol Assessment (“SPA”) and Fast Track designation, as well as Orphan Drug designation.
	Aggregate Merger Consideration
	Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):
	(1)An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”).
	(2)if payable after the Closing, certain payments in an amount of up to $90.0 million in the aggregate, payable in shares of NeoStem Common Stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business being acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).
	The fair value of the net assets acquired in the CSC Acquisition was $20.3 million. The fair value of the consideration paid by NeoStem was valued at $35.3 million, resulting in the recognition of goodwill in the amount of $15.0 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by NeoStem was valued at $24.5 million. The fair value of the milestone payments was valued at $10.8 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement.
	The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):
	Cash and cash equivalents	$	51.2
	Accounts receivable trade, net	45.1
	Prepaids and other current assets	19.2
	Property, plant and equipment, net	1,040.90
	Other assets	201
	Goodwill	14,961.90
	In-Process R&D	35,790.00
	Accounts payable	(333.1		)
	Accrued liabilities	(2,014.1		)
	Deferred tax liability	(14,509.3		)
		$	35,252.80
	The total cost of the acquisition, which is still preliminary, has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The final allocation is pending the receipt of a third-party valuation and the completion of the Company’s internal review, which is expected during fiscal 2014.
	For the period since the acquisition (May 9, 2014 to June 30, 2014), NeoStem recorded $0.01 million in revenues and a net loss of approximately $2.3 million or $0.07 basic and diluted loss per share attributable to CSC.
	Pro Forma Financial Information
	The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts):
		Three Months Ended June 30, 2014						Six Months Ended June 30, 2014
		(As Reported)			(Proforma)			(As Reported)			(Proforma)
	Revenues	$	4,489		$	4,982		$	8,545		$	9,255
	Net loss	$	(12,770	)	$	(13,574	)	$	(26,600	)	$	(29,097	)
	Net loss attributable to NBS	$	(12,605	)	$	(13,409	)	$	(26,287	)	$	(28,784	)
	Net loss per share attributable to NBS	$	(0.40	)	$	(0.36	)	$	(0.88	)	$	(0.82	)
		Three Months Ended June 30, 2013						Six Months Ended June 30, 2013
		(As Reported)			(Proforma)			(As Reported)			(Proforma)
	Revenues	$	4,359		$	4,596		$	6,883		$	7,282
	Net loss	$	(8,626	)	$	(9,830	)	$	(17,490	)	$	(19,963	)
	Net loss attributable to NBS	$	(8,575	)	$	(9,780	)	$	(17,376	)	$	(19,849	)
	Net loss per share attributable to NBS	$	(0.46	)	$	(0.41	)	$	(0.99	)	$	(0.87	)
	The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the acquisition of CSC had been consummated on January 1, 2013, nor are they indicative of future results.

AvailableforSaleSecurities_Not

Available-for-Sale-Securities (Notes)	6 Months Ended
	Jun. 30, 2014
Available-for-sale Securities [Abstract]	'
Cash, Cash Equivalents, and Marketable Securities [Text Block]	'
	Available-for-Sale-Securities
	The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
		June 30, 2014
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Certificate of deposits	$	744	$	—	$	—		$	744
	Money market funds	21,051.00		—		—			21,051.00
	Municipal debt securities	6,581.30		1.1		(0.1		)	6,582.30
	Total	$	28,376.30	$	1.1	$	(0.1	)	$	28,377.30
	Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):
		June 30, 2014
	Cash and cash equivalents	$	27,456.50
	Marketable securities	920.8
	Total	$	28,377.30
	The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):
		30-Jun-14
		Amortized Cost		Estimated Fair Value
	Less than one year	$	28,376.30	$	28,377.30
	Greater than one year	—		—
	Total	$	28,376.30	$	28,377.30

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventories [Abstract]	'
Inventory Disclosure [Text Block]	'
	Inventories
	Inventories, primarily representing work in process for costs incurred on projects at PCT that have not been completed, were $2.0 million and $1.3 million as of June 30, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $2.4 million and $1.5 million of advance billings received as of June 30, 2014 and December 31, 2013, respectively, related to these contracts.

Loss_Per_Share

Loss Per Share	6 Months Ended
	Jun. 30, 2014
Loss Per Share [Abstract]	'
Loss Per Share [Text Block]	'
	Loss Per Share
	For the six months ended June 30, 2014 and 2013, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At June 30, 2014 and 2013, the Company excluded the following potentially dilutive securities:
		June 30,
		2014	2013
	Stock Options	4,204,270	2,647,437
	Warrants	3,623,956	5,430,137
	Restricted Shares	205,231	73,500

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Fair Value Measurements
	Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
	Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
	Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
	The Company classifies the fair value of the warrant derivative liabilities as level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.
	The Company classifies the fair value of contingent consideration obligations as level 3 inputs. The Company has recognized contingent consideration obligations related to the following:
	•	In October 2011, in connection with the Company's acquisition of Amorcyte, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $9.9 million as of June 30, 2014. The change in estimated fair value is based or the impact of the time progression through the Phase 2 clinical trial from December 31, 2013 to June 30, 2014, and has been recorded in other expenses in our consolidated statement of operations.
	•	In May 2014, in connection with the Company's acquisition of CSC, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value recognized in the acquisition in May 2014 was $10.8 million. There was no change in estimated fair value as of June 30, 2014.
	The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014, and December 31, 2013 (in thousands):
			June 30, 2014										December 31, 2013
			Level 1			Level 2		Level 3			Total		Level 1		Level 2		Level 3		Total
	Assets:
	Marketable securities - available for sale		$	—		$	920.8	$	—		$	920.8	$	—	$	—	$	—	$	—
			$	—		$	920.8	$	—		$	920.8	$	—	$	—	$	—	$	—
	Liabilities:
	Warrant derivative liabilities		$	—		$	—	$	—		$	—	$	—	$	—	$	23.2	$	23.2
	Contingent consideration		—			—		20,640.00			20,640.00		—		—		9,450.00		9,450.00
			$	—		$	—	$	20,640.00		$	20,640.00	$	—	$	—	$	9,473.20	$	9,473.20
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the six months ended June 30, 2014 by type of instrument (in thousands):
			Six Months Ended
			June 30, 2014
			Warrants			Contingent Consideration		Total
	Beginning liability balance		$	23.2		$	9,450.00	$	9,473.20
	Amount issued in acquisition		—			10,790.00		10,790.00
	Change in fair value recorded in earnings		—			400		400
	Expiration		(23.2		)	—		(23.2		)
	Ending liability balance		$	—		$	20,640.00	$	20,640.00
	Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Intangible Assets [Text Block]	'
	Goodwill and Other Intangible Assets
	The following table summarizes the changes in the carrying amount of goodwill (in thousands):
		Total
	Balance as of December 31, 2013	$	11,117.70
	Goodwill resulting from the acquisition of CSC	14,961.80
	Balance as of June 30, 2014	$	26,079.50
	The Company's intangible assets and related accumulated amortization as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
				30-Jun-14								31-Dec-13
		Useful Life		Gross			Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00		$	(345.1	)	$	654.9	$	1,000.00	$	(295.1	)	$	704.9
	Manufacturing technology	10 years		3,900.00			(1,345.9		)	2,554.10		3,900.00		(1,150.9		)	2,749.10
	Tradename	10 years		800			(276.1		)	523.9		800		(236.1		)	563.9
	In process R&D	Indefinite		45,190.00			—			45,190.00		9,400.00		—			9,400.00
	Patent rights	19 years		669			(228.9		)	440.1		669		(211.3		)	457.7
	Total Intangible Assets			$	51,559.00		$	(2,196.0	)	$	49,363.00	$	15,769.00	$	(1,893.4	)	$	13,875.60
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
			Six Months Ended June 30,
			2014			2013
	Cost of revenue		$	158.4		$	195
	Research and development		54.2			17.6
	Selling, general and administrative		90			90
	Total		$	302.6		$	302.6
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2014	$	302.6
	2015	605.2
	2016	605.2
	2017	605.2
	2018	605.2
	Thereafter	46,639.60
		$	49,363.00

Accrued_Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Accrued Liabilities
	Accrued liabilities as of June 30, 2014 and December 31, 2013 were as follows (in thousands):
		June 30, 2014		31-Dec-13
	Salaries, employee benefits and related taxes	$	1,443.20	$	2,325.80
	Professional fees	651.7		544.8
	License fees	100		500
	Other	392.4		647.4
		$	2,587.30	$	4,018.00

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt [Abstract]	'
Debt Disclosure [Text Block]	'
	Debt
	Notes Payable
	As of June 30, 2014 and December 31, 2013, the Company had notes payable of approximately $1.8 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
	Mortgages Payable
	In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”). The First Mortgage is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The First Mortgage is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The First Mortgage had previously been subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. The outstanding balance was approximately $2.4 million and $2.5 million at June 30, 2014 and December 31, 2013, respectively, of which $130,000 is payable within twelve months as of June 30, 2014.
	In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1.0 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage had been subject to an annual financial covenant starting December 31, 2011. The Second Mortgage is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.7 million and $0.8 million at June 30, 2014 and December 31, 2013, respectively, of which $89,000 is payable within twelve months as of June 30, 2014.
	In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A., whereby (i) prior debt service coverage and total debt to tangible net worth financial covenant ratios were replaced with a minimum unencumbered liquidity covenant, and (ii) prior guarantors were released (see Note 14) and replaced with NeoStem, PCT, and NeoStem Family Storage. The Company is in compliance with the new minimum unencumbered liquidity covenant.

Shareholders_Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2014
Shareholdersb Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Shareholders' Equity
	Reverse Stock Split
	On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.
	Equity Issuances
	In September 2011, the Company entered into a common stock purchase agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement.
	In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock was based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we issued 150,000 shares of our common stock to Aspire Capital. During the six months ended June 30, 2014, the Company issued 0.7 million shares of Common Stock under the provisions the Purchase Agreement with Aspire for gross proceeds of approximately $4.4 million.
	Option Exercises
	During the six months ended ended June 30, 2014, option holders exercised an aggregate of 41,136 options at exercise prices between of $5.20 and $6.20 per share for gross proceeds of approximately $0.2 million.
	Warrant Exercises
	During the six months ended ended June 30, 2014, warrant holders exercised an aggregate of 265,250 warrants at exercise price between $5.10 and $14.50 per share for gross proceeds of approximately $1.4 million.
	Stock Options and Warrants
	The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2014:
		Stock Options								Warrants
		Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
	Outstanding at December 31, 2013	2,932,191		$	11.19		6.8	$	1,658.10	4,898,266		$	16.5	2.6	$	1,811.00
	Changes during the period:
	Granted	1,653,325		$	7.05					2,722		$	12.26
	Exercised	(41,136	)	$	5.6					(265,250	)	$	5.18
	Forfeited	(189,454	)	$	6.34					(100,108	)	$	70
	Expired	(150,656	)	$	15.78					(911,674	)	$	23.97
	Outstanding at June 30, 2014	4,204,270		$	9.67		7.6	$	1,657.40	3,623,956		$	13.96	2.6	$	1,080.20
	Vested at June 30, 2014 or expected to vest in the future	3,891,887		$	9.86		7.4	$	1,592.80	3,623,956		$	13.96	2.6	$	1,080.20
	Vested at June 30, 2014	2,533,802		$	11.16		6.5	$	1,123.20	3,611,456		$	13.98	2.6	$	1,080.20
	During the six months ended June 30, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):
		Six Months Ended June 30,
		2014			2013
	Number of Common Stock Purchase Warrants Issued	—			20,407
	Value of Common Stock Purchase Warrants Issued	$	—		$	71.6
	Restricted Stock
	During the six months ended June 30, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):
		Six Months Ended June 30,
		2014			2013
	Number of Restricted Stock Issued	456,709			304,402
	Value of Restricted Stock Issued	$	3,389.70		$	1,858.30
	The weighted average estimated fair value of restricted stock issued for services in the six months ended June 30, 2014 and 2013 was $7.42 and $6.10 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

ShareBased_Compensation_Notes

Share-Based Compensation (Notes)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Share-Based Compensation
	Share-based Compensation
	We utilize share-based compensation in the form of stock options, warrants and restricted stock.  The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Cost of goods sold	$	98.5	$	58.5	$	236.6	$	145
	Research and development	371.6		129.8		848.4		347.1
	Selling, general and administrative	1,289.60		907.4		4,568.50		2,822.10
	Total share-based compensation expense	$	1,759.70	$	1,095.70	$	5,653.50	$	3,314.20
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at June 30, 2014 were as follows (dollars in thousands):
		Stock Options		Warrants		Restricted Stock
	Unrecognized compensation cost	$	6,814.90	$	33.4	$	262.9
	Expected weighted-average period in years of compensation cost to be recognized	5.02		1.05		0.19
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2014 and 2013 were as follows (dollars in thousands):
		Stock Options				Warrants
		Six Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Total fair value of shares vested	$	2,552.20	$	1,646.30	$	15	$	80.9
	Weighted average estimated fair value of shares granted	$	4.92	$	4.58	$	—	$	3.51

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Income Taxes
	As of December 31, 2013, the Company had approximately $110.6 million of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2033.
	In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.
	Deferred tax liabilities were $19.0 million and $4.4 million as of June 30, 2014 and December 31, 2013, and relate to the taxable temporary differences on (i) the goodwill recognized in the PCT acquisition in 2011, (ii) the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011, and (iii) the in-process R&D intangible asset recognized in the CSC acquisition in 2014. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset.
	As of June 30, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions [Text Block]	'
	Related Party Transactions
	In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 10). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, including Dr. Pecora, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies [Text Block]	'
	Commitments and Contingencies
	Lease Commitments
	The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for additional space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future and shall extend through 2018. This property is used as the Company's corporate headquarters. In connection with the acquisition of CSC on May 8, 2014, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017.
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2014 are as follows (in thousands):
	Years ended	Operating Leases
	2014	$	675.3
	2015	1,160.50
	2016	997.9
	2017	697.8
	2018	5.9
	Total minimum lease payments	$	3,537.40
	Expense incurred under operating leases was approximately $0.3 million and $0.3 million for the three months ended June 30, 2014 and 2013, respectively. Expense incurred under operating leases was approximately $0.5 million and $0.6 million for the six months ended June 30, 2014 and 2013, respectively.
	Contingencies
	Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Schedule of Cash and Cash Equivalents [Table Text Block]	'
	Cash and Cash Equivalents
	Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.
Marketable Securities, Policy [Policy Text Block]	'
	Marketable Securities
	The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
Inventory Disclosure [Text Block]	'
	Inventories
	The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory primarily represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill and Other Intangible Assets
	Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") programs acquired in the Amorcyte and CSC acquisitions, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.
	The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value.
	Amortized intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.
	Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.
	Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended June 30, 2014 and 2013, clinical services reimbursements were $1.1 million and $0.4 million, respectively. For the six months ended June 30, 2014 and 2013, clinical services reimbursements were $1.8 million and $0.8 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

The_Business_Tables

The Business (Tables)	6 Months Ended
	Jun. 30, 2014
The Business [Abstract]	'
Subsidiary [Table Text Block]	'
	.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	90%	United States of America
	PCT Allendale, LLC	100%	United States of America
	NeoStem Oncology, LLC (2)	100%	United States of America

Acquisition_Tables

Acquisition (Tables)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Business Acquisition, Pro Forma Information [Table Text Block]	'
	The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts):
		Three Months Ended June 30, 2014						Six Months Ended June 30, 2014
		(As Reported)			(Proforma)			(As Reported)			(Proforma)
	Revenues	$	4,489		$	4,982		$	8,545		$	9,255
	Net loss	$	(12,770	)	$	(13,574	)	$	(26,600	)	$	(29,097	)
	Net loss attributable to NBS	$	(12,605	)	$	(13,409	)	$	(26,287	)	$	(28,784	)
	Net loss per share attributable to NBS	$	(0.40	)	$	(0.36	)	$	(0.88	)	$	(0.82	)
		Three Months Ended June 30, 2013						Six Months Ended June 30, 2013
		(As Reported)			(Proforma)			(As Reported)			(Proforma)
	Revenues	$	4,359		$	4,596		$	6,883		$	7,282
	Net loss	$	(8,626	)	$	(9,830	)	$	(17,490	)	$	(19,963	)
	Net loss attributable to NBS	$	(8,575	)	$	(9,780	)	$	(17,376	)	$	(19,849	)
	Net loss per share attributable to NBS	$	(0.46	)	$	(0.41	)	$	(0.99	)	$	(0.87	)
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):
	Cash and cash equivalents	$	51.2
	Accounts receivable trade, net	45.1
	Prepaids and other current assets	19.2
	Property, plant and equipment, net	1,040.90
	Other assets	201
	Goodwill	14,961.90
	In-Process R&D	35,790.00
	Accounts payable	(333.1		)
	Accrued liabilities	(2,014.1		)
	Deferred tax liability	(14,509.3		)
		$	35,252.80

AvailableforSaleSecurities_Tab

Available-for-Sale-Securities (Tables)	6 Months Ended
	Jun. 30, 2014
Available-for-sale Securities [Abstract]	'
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	'
	The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):
		June 30, 2014
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Certificate of deposits	$	744	$	—	$	—		$	744
	Money market funds	21,051.00		—		—			21,051.00
	Municipal debt securities	6,581.30		1.1		(0.1		)	6,582.30
	Total	$	28,376.30	$	1.1	$	(0.1	)	$	28,377.30
Marketable Securities [Table Text Block]	'
	Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):
		June 30, 2014
	Cash and cash equivalents	$	27,456.50
	Marketable securities	920.8
	Total	$	28,377.30
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):
		30-Jun-14
		Amortized Cost		Estimated Fair Value
	Less than one year	$	28,376.30	$	28,377.30
	Greater than one year	—		—
	Total	$	28,376.30	$	28,377.30

Loss_Per_Share_Tables

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Loss Per Share [Abstract]	'
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]	'
	At June 30, 2014 and 2013, the Company excluded the following potentially dilutive securities:
		June 30,
		2014	2013
	Stock Options	4,204,270	2,647,437
	Warrants	3,623,956	5,430,137
	Restricted Shares	205,231	73,500

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]	'
	•	In October 2011, in connection with the Company's acquisition of Amorcyte, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $9.9 million as of June 30, 2014. The change in estimated fair value is based or the impact of the time progression through the Phase 2 clinical trial from December 31, 2013 to June 30, 2014, and has been recorded in other expenses in our consolidated statement of operations.
	•	In May 2014, in connection with the Company's acquisition of CSC, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value recognized in the acquisition in May 2014 was $10.8 million. There was no change in estimated fair value as of June 30, 2014.
	The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014, and December 31, 2013 (in thousands):
			June 30, 2014										December 31, 2013
			Level 1			Level 2		Level 3			Total		Level 1		Level 2		Level 3		Total
	Assets:
	Marketable securities - available for sale		$	—		$	920.8	$	—		$	920.8	$	—	$	—	$	—	$	—
			$	—		$	920.8	$	—		$	920.8	$	—	$	—	$	—	$	—
	Liabilities:
	Warrant derivative liabilities		$	—		$	—	$	—		$	—	$	—	$	—	$	23.2	$	23.2
	Contingent consideration		—			—		20,640.00			20,640.00		—		—		9,450.00		9,450.00
			$	—		$	—	$	20,640.00		$	20,640.00	$	—	$	—	$	9,473.20	$	9,473.20
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the six months ended June 30, 2014 by type of instrument (in thousands):
			Six Months Ended
			June 30, 2014
			Warrants			Contingent Consideration		Total
	Beginning liability balance		$	23.2		$	9,450.00	$	9,473.20
	Amount issued in acquisition		—			10,790.00		10,790.00
	Change in fair value recorded in earnings		—			400		400
	Expiration		(23.2		)	—		(23.2		)
	Ending liability balance		$	—		$	20,640.00	$	20,640.00

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
	The following table summarizes the changes in the carrying amount of goodwill (in thousands):
		Total
	Balance as of December 31, 2013	$	11,117.70
	Goodwill resulting from the acquisition of CSC	14,961.80
	Balance as of June 30, 2014	$	26,079.50
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
	The Company's intangible assets and related accumulated amortization as of June 30, 2014 and December 31, 2013 consisted of the following (in thousands):
				30-Jun-14								31-Dec-13
		Useful Life		Gross			Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00		$	(345.1	)	$	654.9	$	1,000.00	$	(295.1	)	$	704.9
	Manufacturing technology	10 years		3,900.00			(1,345.9		)	2,554.10		3,900.00		(1,150.9		)	2,749.10
	Tradename	10 years		800			(276.1		)	523.9		800		(236.1		)	563.9
	In process R&D	Indefinite		45,190.00			—			45,190.00		9,400.00		—			9,400.00
	Patent rights	19 years		669			(228.9		)	440.1		669		(211.3		)	457.7
	Total Intangible Assets			$	51,559.00		$	(2,196.0	)	$	49,363.00	$	15,769.00	$	(1,893.4	)	$	13,875.60
Schedule of Amortization Expense [Table Text Block]	'
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
			Six Months Ended June 30,
			2014			2013
	Cost of revenue		$	158.4		$	195
	Research and development		54.2			17.6
	Selling, general and administrative		90			90
	Total		$	302.6		$	302.6
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2014	$	302.6
	2015	605.2
	2016	605.2
	2017	605.2
	2018	605.2
	Thereafter	46,639.60
		$	49,363.00

Accrued_Liabilities_Accrued_Li

Accrued Liabilities Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities as of June 30, 2014 and December 31, 2013 were as follows (in thousands):
		June 30, 2014		31-Dec-13
	Salaries, employee benefits and related taxes	$	1,443.20	$	2,325.80
	Professional fees	651.7		544.8
	License fees	100		500
	Other	392.4		647.4
		$	2,587.30	$	4,018.00

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Shareholdersb Equity [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2014:
		Stock Options								Warrants
		Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
	Outstanding at December 31, 2013	2,932,191		$	11.19		6.8	$	1,658.10	4,898,266		$	16.5	2.6	$	1,811.00
	Changes during the period:
	Granted	1,653,325		$	7.05					2,722		$	12.26
	Exercised	(41,136	)	$	5.6					(265,250	)	$	5.18
	Forfeited	(189,454	)	$	6.34					(100,108	)	$	70
	Expired	(150,656	)	$	15.78					(911,674	)	$	23.97
	Outstanding at June 30, 2014	4,204,270		$	9.67		7.6	$	1,657.40	3,623,956		$	13.96	2.6	$	1,080.20
	Vested at June 30, 2014 or expected to vest in the future	3,891,887		$	9.86		7.4	$	1,592.80	3,623,956		$	13.96	2.6	$	1,080.20
	Vested at June 30, 2014	2,533,802		$	11.16		6.5	$	1,123.20	3,611,456		$	13.98	2.6	$	1,080.20
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	During the six months ended June 30, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):
		Six Months Ended June 30,
		2014			2013
	Number of Common Stock Purchase Warrants Issued	—			20,407
	Value of Common Stock Purchase Warrants Issued	$	—		$	71.6
Restricted Stock [Table Text Block]	'
	During the six months ended June 30, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):
		Six Months Ended June 30,
		2014			2013
	Number of Restricted Stock Issued	456,709			304,402
	Value of Restricted Stock Issued	$	3,389.70		$	1,858.30

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Cost of goods sold	$	98.5	$	58.5	$	236.6	$	145
	Research and development	371.6		129.8		848.4		347.1
	Selling, general and administrative	1,289.60		907.4		4,568.50		2,822.10
	Total share-based compensation expense	$	1,759.70	$	1,095.70	$	5,653.50	$	3,314.20
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at June 30, 2014 were as follows (dollars in thousands):
		Stock Options		Warrants		Restricted Stock
	Unrecognized compensation cost	$	6,814.90	$	33.4	$	262.9
	Expected weighted-average period in years of compensation cost to be recognized	5.02		1.05		0.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2014 and 2013 were as follows (dollars in thousands):
		Stock Options				Warrants
		Six Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Total fair value of shares vested	$	2,552.20	$	1,646.30	$	15	$	80.9
	Weighted average estimated fair value of shares granted	$	4.92	$	4.58	$	—	$	3.51

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2014 are as follows (in thousands):
	Years ended	Operating Leases
	2014	$	675.3
	2015	1,160.50
	2016	997.9
	2017	697.8
	2018	5.9
	Total minimum lease payments	$	3,537.40

The_Business_Details

The Business (Details) (USD $)	0 Months Ended		6 Months Ended
	Jun. 18, 2012	Jun. 19, 2012	Jun. 30, 2014
	segment	segment
The Company [Line Items]	'	'	'
Change in Ownership in Subsidiary	'	'	$0
Number of Reporting Segments	3	1	'
Noncontrolling Interest [Member]	'	'	'
The Company [Line Items]	'	'	'
Change in Ownership in Subsidiary	'	'	$86,618

The_Business_Principal_of_cons

The Business Principal of consolidation (Details)	6 Months Ended
	Jun. 30, 2014
NeoStem, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Minority Interest Ownership Percentage By Parent [String]	'ParentB Company
NeoStem Therapies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
China Biopharmaceuticals Holdings, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Suzhou Erye Pharmaceuticals Company Ltd. [Member] | CHINA	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	51.00%
Progenitor Cell Therapy, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1
Athelos Corporation [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	90.00%
Minority Interest Ownership Percentage By Parent [String]	'0.90
PCT Allendale, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1
NeoStem Oncology [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Summary of Significant Accounting Policies [Abstract]	'	'	'	'
Clinical Services Reimbursement	$1.10	$0.40	$1.80	$0.80

Acquisition_Details

Acquisition (Details) (USD $)	2 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	8-May-14	Dec. 31, 2013
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Revenues	'	$4,488,932	$4,359,406	$8,544,507	$6,883,318	'	'
Net loss	'	-12,769,492	-8,625,641	-26,599,576	-17,489,971	'	'
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	10,000	'	'	'	'	'	'
Common Stock, Shares, Issued	34,939,223	34,939,223	'	34,939,223	'	5,329,593	27,196,537
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	'	'	'	'	'	90,000,000	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	20,300,000	20,300,000	'	20,300,000	'	'	'
Acquisition-related contingent consideration	20,640,000	20,640,000	'	20,640,000	'	10,800,000	9,450,000
Business Acquisition, Transaction Costs	'	'	'	'	'	35,300,000	'
Cash and cash equivalents	'	'	'	'	'	51,200	'
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively	'	'	'	'	'	45,100	'
Prepaid expenses and other current assets	'	'	'	'	'	19,200	'
Property, plant and equipment, net	'	'	'	'	'	1,040,900	'
Other assets	'	'	'	'	'	201,000	'
Goodwill	26,079,536	26,079,536	'	26,079,536	'	14,961,900	11,117,770
Equity Issued in Business Combination, Fair Value Disclosure	'	'	'	'	'	24,500,000	'
Intangible assets, net	'	'	'	'	'	35,790,000	'
Accounts Payable, Current	'	'	'	'	'	-333,100	'
Accrued Liabilities, Current	'	'	'	'	'	-2,014,100	'
Deferred Tax Liabilities, Net, Noncurrent	'	'	'	'	'	-14,509,300	'
Business Acquisition, Pro Forma Net Income (Loss)	-2,300,000	'	'	'	'	'	'
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	($0.07)	($0.40)	($0.46)	($0.88)	($0.99)	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	'	'	'	'	'	35,252,800	'
NeoStem Oncology [Member]	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Business Acquisition, Pro Forma Revenue	'	4,982,000	4,596,000	9,255,000	7,282,000	'	'
Business Acquisition, Pro Forma Net Income (Loss)	'	-13,574,000	-9,830,000	-29,097,000	-19,963,000	'	'
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	'	-13,409,000	-9,780,000	-28,784,000	-19,849,000	'	'
Business Acquisition, Pro Forma Earnings Per Share, Diluted	'	($0.36)	($0.41)	($0.82)	($0.87)	'	'
NeoStem, Inc. [Member]	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Revenues	'	4,489,000	4,359,000	8,545,000	6,883,000	'	'
Net loss	'	-12,770,000	-8,626,000	-26,600,000	-17,490,000	'	'
Net Income (Loss) Attributable to Parent	'	-12,605,000	-8,575,000	-26,287,000	-17,376,000	'	'
Goodwill	$26,079.50	$26,079.50	'	$26,079.50	'	'	$11,117.70
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	'	($0.40)	($0.46)	($0.88)	($0.99)	'	'

AvailableforSaleSecurities_Sch

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details) (USD $)	Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale Securities, Amortized Cost Basis	$28,376,300
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	1,100
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	-100
Certificates of Deposit, at Carrying Value	28,377,300
Municipal Bonds [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale Securities, Amortized Cost Basis	6,581,300
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	1,100
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	100
Certificates of Deposit, at Carrying Value	6,582,300
Money Market Funds [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale Securities, Amortized Cost Basis	21,051,000
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0
Deferred Tax Assets, Unrealized Losses on Trading Securities	0
Certificates of Deposit, at Carrying Value	21,051,000
Certificates of Deposit [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale Securities, Amortized Cost Basis	744,000
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0
Deferred Tax Assets, Unrealized Losses on Trading Securities	0
Certificates of Deposit, at Carrying Value	$744,000

AvailableforSaleSecurities_Cla

Available-for-Sale-Securities Classification of the available-for-sale securities (Details) (USD $)	Jun. 30, 2014
Available-for-sale Securities [Abstract]	'
Cash	$27,456,500
Marketable securities	920,800
Total	$28,377,300

AvailableforSaleSecurities_Ava

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details) (USD $)	Jun. 30, 2014
Available-for-sale Securities [Abstract]	'
Less than one year, Amortized Cost	$28,376,300
Less than one year, Fair Value	28,377,300
Amortized Cost	28,376,300
Estimated Fair Value	$28,377,300

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]	'	'
Inventory	$2,033,011	$1,270,223
Multiple Stage Contracts [Member]	'	'
Schedule of Inventory [Line Items]	'	'
Deferred Revenue	$2,400,000	$1,500,000

Loss_Per_Share_Details

Loss Per Share (Details)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Warrants	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,623,956	5,430,137
Stock Options [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,204,270	2,647,437
Restricted Stock [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	205,231	73,500

Fair_Value_Measurements_Fair_v

Fair Value Measurements Fair value hierarchy the Companybs financial assets and liabilities (Details) (USD $)

Jun. 30, 2014

8-May-14

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Assets, Total [Member]

Assets, Total [Member]

Contingent Consideration Classified as Equity [Member]

Contingent Consideration Classified as Equity [Member]

Amorcyte, LLC [Member]

Amorcyte, LLC [Member]

Warrants

Warrants

Contingent Consideration Classified as Equity [Member]

Contingent Consideration Classified as Equity [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related contingent consideration

$20,640,000

$10,800,000

$9,450,000

'

'

'

'

'

'

'

'

$20,640,000

$9,450,000

$9,900,000

$9,500,000

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

'

90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Basis for Amount

'

'

'

'

'

'

'

'

'

'

'

'10790.0

'

'

'

'

'

'

'

Available-for-sale Securities

920,800

'

0

0

0

920,800

0

0

0

'

'

'

'

'

'

'

'

'

'

Marketable securities

920,827

'

0

0

0

920,800

0

0

0

920,800

0

'

'

'

'

'

'

'

'

Warrant Derivative Liabilities

0

'

23,200

0

0

0

0

0

23,200

'

'

'

'

'

'

0

23,200

'

'

Contingent Consideration Classified as Equity, Fair Value Disclosure

'

'

'

0

0

0

0

20,640,000

9,450,000

'

'

'

'

'

'

'

'

20,640,000

9,450,000

Accrued Liabilities and Other Liabilities

$20,640,000

'

$9,473,200

$0

$0

$0

$0

$20,640,000

$9,473,200

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Financ

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2011	8-May-14	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Percentage of Net Sales	'	'	10.00%	'	'
License Costs	'	'	$0.30	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'	'
Warrant Derivative Liabilities	0	'	'	'	23,200
Acquisition-related contingent consideration	20,640,000	'	'	10,800,000	9,450,000
Accrued Liabilities and Other Liabilities	20,640,000	'	'	'	9,473,200
Warrants Issued During Period, Value	0	71,600	'	'	'
Business Combination, Consideration Transferred, Liabilities Incurred	10,790,000	'	'	'	'
Change in acquisition-related contingent consideration	400,000	0	'	'	'
Fair Value, Option, Changes in Fair Value, Gain (Loss)	400,000	'	'	'	'
Expiration	-23,200	'	'	'	'
Warrant Derivative Liabilities	0	'	'	'	23,200
Warrants	'	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'	'
Warrants Issued During Period, Value	0	'	'	'	'
Fair Value Adjustment of Warrants	0	'	'	'	'
Expiration	-23,200	'	'	'	'
Contingent Consideration Classified as Equity [Member]	'	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'	'
Acquisition-related contingent consideration	20,640,000	'	'	'	9,450,000
Business Combination, Contingent Consideration Arrangements, Basis for Amount	'10790.0	'	'	'	'
Change in acquisition-related contingent consideration	400,000	'	'	'	'
Expiration	$0	'	'	'	'

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) (USD $)

Jun. 30, 2014

8-May-14

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Customer Lists [Member]

Customer Lists [Member]

Manufacturing Technology [Member]

Manufacturing Technology [Member]

Trade Names [Member]

Trade Names [Member]

In Process R and D [Member]

In Process R and D [Member]

VSEL Patent Rights [Member]

VSEL Patent Rights [Member]

NeoStem, Inc. [Member]

NeoStem, Inc. [Member]

NeoStem Oncology [Member]

Goodwill [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

$26,079,536

$14,961,900

$11,117,770

'

'

'

'

'

'

'

'

'

'

$26,079.50

$11,117.70

'

Goodwill, Acquired During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,961.80

Goodwill

26,079,536

14,961,900

11,117,770

'

'

'

'

'

'

'

'

'

'

26,079.50

11,117.70

'

Finite-Lived Intangible Assets, Gross

51,559,000

'

15,769,000

1,000,000

1,000,000

3,900,000

3,900,000

800,000

800,000

45,190,000

9,400,000

669,000

669,000

'

'

'

Finite-Lived Intangible Assets, Accumulated Amortization

-2,196,000

'

-1,893,400

-345,100

-295,100

-1,345,900

-1,150,900

-276,100

-236,100

0

0

-228,900

-211,300

'

'

'

Finite-Lived Intangible Assets, Future Amortization Expense

$49,363,000

'

$13,875,600

$654,900

$704,900

$2,554,100

$2,749,100

$523,900

$563,900

$45,190,000

$9,400,000

$440,100

$457,700

'

'

'

Finite Lived Intangible Assets, Useful Life [String]

'

'

'

'

'

'

'

'

'

'Indefinite

'

'

'

'

'

'

Finite-Lived Intangible Assets, Useful Life

'

'

'

'10 years

'

'10 years

'

'10 years

'

'

'

'19 years

'

'

'

'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$302,600	$302,600
Cost of revenue	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	158,400	195,000
Research and development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	54,200	17,600
Selling, general and administrative	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$90,000	$90,000

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Goodwill (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Goodwill [Abstract]	'	'
Future Amortization Expense, Year One	$302,600	'
Future Amortization Expense, Year Two	605,200	'
Future Amortization Expense, Year Three	605,200	'
Future Amortization Expense, Year Four	605,200	'
Future, Amortization Expense, Year Five	605,200	'
Thereafter	46,639,600	'
Finite-Lived Intangible Assets, Future Amortization Expense	$49,363,000	$13,875,600

Accrued_Liabilities_Accrued_Li1

Accrued Liabilities Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]	'	'
Salaries, employee benefits and related taxes	$1,443.20	$2,325.80
Professional fees	651.7	544.8
License fees	100	500
Other	392.4	647.4
Accrued Liabilities	$2,587.30	$4,018

Debt_Details

Debt (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Oct. 31, 2007	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 06, 2010	Jun. 30, 2014	Dec. 31, 2013
			Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]
							Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Notes Payable	$1,800,000	$900,000	'	'	'	'	'	'	'
Purchase of condominium units	'	'	0	'	'	'	'	'	'
Debt Instrument, Frequency of Periodic Payment	'	'	'monthly payments	'	'	'	'	'	'
Debt Instrument, Periodic Payment	'	'	'	'	'	20,766	'	'	'
Debt Instrument, Periodic Payment, Interest	'	'	'	5.00%	'	'	6.00%	'	'
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	'	'	'	2,400,000	2,500,000	'	'	720,300	763,000
Mortgage Loan Repayble Amount within 12 months	'	'	'	'	'	130,000	'	89,000	'
Mortgage Loans on Real Estate, New Mortgage Loans	'	'	$3.10	'	'	'	$1,000,000	'	'
Debt Instrument, Period of Loan	'	'	'	'	'	'	'124 months	'	'
Debt Instrument, Period of Fixed Interest Rate	'	'	'	'	'	'	'64 months	'	'

Shareholders_Equity_Reverse_St

Shareholders' Equity Reverse Stock Split (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jul. 26, 2013
Statement of Stockholders' Equity [Abstract]	'	'	'
Common Stock, Par Value	$0.00	$0.00	$0.00

Shareholders_Equity_Equity_Iss

Shareholders' Equity Equity Issuances (Details) (USD $)	6 Months Ended							6 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	8-May-14	Dec. 31, 2013	Jun. 30, 2014	Mar. 31, 2014	Sep. 28, 2011	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
					Aspire Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Aegis Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Maximum [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'
Committment Value Under Purchase Agreement	'	'	'	'	'	$20,000,000	'	'	'	'
Term Of Agreement In Months	'	'	'	'	24	'	24	'	'	'
Discount Applied To Weighted Average Price	'	'	'	'	5.00%	'	'	'	'	'
Shares, Issued	'	'	'	'	'	'	'	800,000	'	'
Proceeds from Issuance of Common Stock Gross	'	'	'	'	'	'	'	5,600,000	'	'
Common Stock, Shares, Issued	34,939,223	'	5,329,593	27,196,537	'	'	'	'	150,000	'
Purchase Commitment, Remaining Minimum Amount Committed	'	'	'	'	'	'	'	'	30,000,000	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	'	'	'	700,000	'	'
Net proceeds from issuance of common stock	10,149,438	14,248,148	'	'	'	'	'	4,400,000	'	'
Stock Option Exercise	41,136	'	'	'	'	'	'	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	'	'	'	'	'	'	'	'	'	$6.20
Proceeds from Stock Options Exercised	$200,000	'	'	'	'	'	'	'	'	'

Shareholders_Equity_Warrant_Ex

Shareholders' Equity Warrant Exercises (Details) (USD $)	0 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2012	Sep. 30, 2012	Jun. 30, 2014
		Private Placement [Member]	Warrant holder A [Member]
Stock Options and Warrants [Line Items]	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	265,250
Investment Warrants, Exercise Price	$14.50	$5.10	'
Proceeds from Issuance of Warrants	'	'	$1.40

Shareholders_Equity_Stock_opti

Shareholders' Equity Stock options and warrants (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stock Options and Warrants [Line Items]	'	'	'
Stock Issued During Period, Shares, Other	0	20,407	'
Warrants Issued During Period, Value	$0	$71,600	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	1,657,400	1,658,100	'
Common Stock Warrants, Shares	3,623,956	'	4,898,266
Weighted Average Exercise Price, Warrants Outstanding	13.96	'	16.5
Weighted Average Remaining Contractual Term warrant outstanding	'2 years 7 months 17 days	'2 years 7 months 17 days	'
Aggregate Intrinsic Value, Warrants Outstanding	1,080,200	1,811,000	'
Warrants Granted	2,722	'	'
Weighted Average Exercise Price, Warrants Granted	$12.26	'	'
Warrants Exercised	-265,250	'	'
Weighted Average Exercise Price, Warrants Exercised	$5.18	'	'
Warrants Expired	-100,108	'	'
Weighted Average Exercise Price, Warrants Expired	$70	'	'
Warrants Canceled	-911,674	'	'
Weighted Average Exercise Price, Warrants Canceled	$23.97	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	1,592,800	'	'
shares, vested and expected to vest	3,623,956	'	'
Weighted Average Exercise Price, Warrants vested & expected to vest	13.96	'	'
Aggregate Intrinsic Value, Warrants vested and expected to vest	1,080,200	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	1,123,200	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,611,456	'	'
Weighted Average Exercise Price, Warrants Exercisable	13.98	'	'
weighted Average Remaining Contractual Term, warrants vested	'2 years 7 months 13 days	'	'
Aggregate Intrinsic Value, Warrants vested	$1,080,200	'	'
Warrants	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Weighted average estimated fair value of shares granted	$0	'	$3.51
US Equity Plan [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,204,270	'	2,932,191
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$9.67	'	$11.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'7 years 6 months 26 days	'6 years 9 months 22 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,653,325	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$7.05	'	'
Stock Options Exercised	-41,136	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$5.60	'	'
Stock Options Expired	-189,454	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$6.34	'	'
Stock Options Forfeited	-150,656	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$15.78	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,891,887	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$9.86	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	'7 years 4 months 28 days	'	'
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	'2 years 7 months 17 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,533,802	'	'
Weighted average estimated fair value of shares granted	$11.16	'	'
Options, Vested, weighted Average Remaining Contractual Term	'6 years 6 months 18 days	'	'
Minimum [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$5.20	'	'
Maximum [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$6.20	'	'

Shareholders_Equity_Restricted

Shareholders' Equity Restricted Stock (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	456,709	304,402
Stock Issued During Period, Value, Restricted Stock Award, Gross	$3,389,700	$1,858,300
weighted average estimated fair value of restricted stock	$7.42	$6.10

ShareBased_Compensation_ShareB

Share-Based Compensation Share-Based Compensation (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Stock Option [Member]

Warrants

Warrants

Warrants

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Cost of revenue

Cost of revenue

Cost of revenue

Cost of revenue

Research and development

Research and development

Research and development

Research and development

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Stock Option [Member]

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

$1,759,700

$1,095,700

$5,653,500

$3,314,200

'

'

'

'

'

'

'

$98,500

$58,500

$236,600

$145,000

$371,600

$129,800

$848,400

$347,100

$1,289,600

$907,400

$4,568,500

$2,822,100

'

'

Unrecognized compensation cost

'

'

'

'

6,814,900

33,400

'

'

'

'

262,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected weighted-average period in years of compensation cost to be recognized

'

'

'

'

'5 years 7 days

'1 year 18 days

'

'

'

'

'2 months 9 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of shares vested

'

'

'

'

'

$15,000

$80,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,552,200

$1,646,300

Weighted average estimated fair value of shares granted

'

'

'

'

'

$0

'

$3.51

$4.92

$4.58

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Net_Operating_Los

Income Taxes Net Operating Loss Carry Forward (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'	'
Operating Loss Carryforwards	'	$110,600,000
Deferred Tax Liabilities, Net, Noncurrent	$18,983,288	$4,379,226

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating Leases, Future Minimum Payments Due [Abstract]	'	'	'	'
2013	$675,300	'	$675,300	'
2014	1,160,500	'	1,160,500	'
2015	997,900	'	997,900	'
2016	697,800	'	697,800	'
Thereafter	5,900	'	5,900	'
Total minimum lease payments	3,537,400	'	3,537,400	'
Operating Leases, Rent Expense	$300,000	$300,000	$500,000	$600,000